Synchronous primary sigmoid colon cancer and primary thyroid cancer followed by a malignant tumor of the kidney: Case report of multiple primary cancer and review of the literature

Peng,Cheng; Li,Zequn; Gao,Huijie; Zou,Xueqing; Wang,Xiao; Zhou,Changkuo; Niu,Jun

doi:10.3892/ol.2018.9867

Synchronous primary sigmoid colon cancer and primary thyroid cancer followed by a malignant tumor of the kidney: Case report of multiple primary cancer and review of the literature

Authors:
- Cheng Peng
- Zequn Li
- Huijie Gao
- Xueqing Zou
- Xiao Wang
- Changkuo Zhou
- Jun Niu
View Affiliations

Affiliations: Department of Hepatobiliary Surgery, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China, Department of Pathology, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China, Department of Urology Surgery, Hospital of Shandong University, Jinan, Shandong 250012, P.R. China
Published online on: December 24, 2018 https://doi.org/10.3892/ol.2018.9867
Pages: 2479-2484

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Multiple primary cancer (MPC) is relatively rare. With the development of diagnostic and anti‑cancer therapeutic techniques, the incidence of MPC is rising annually. However, the incidence of triple or quadruple cancers in a single patient remains low. In this report, the case of a 58‑year‑old male with triple malignant cancer is outlined. Synchronous sigmoid colon cancer and thyroid cancer were diagnosed in May 2015; on subsequent re‑examination, metastasis to the liver and a malignant kidney tumor were also identified. The diagnosis was established via computed tomography (CT), Positron emission tomography‑CT (PET‑CT) and other laboratory examination results, including analysis of tumor markers and liver function, and was confirmed by pathological diagnosis. The patient underwent radical surgery and standardized chemotherapy. Through literature review, the definition, characteristics, classification, incidence, possible causes of and treatment strategies for MPC were more clearly understood. In addition, immunohistochemical staining of integrin αvβ6 was performed on patient tissue specimens, where integrin αvβ6 expression was confirmed in cancer of the colon, thyroid and liver, as a result of colonic metastasis. Therefore, the involvement of integrin αvβ6 in the malignant progression of MPC was hypothesized, which may aid the investigation of MPC etiology in the future.

View Figures

View References

1	Ueno M, Muto T, Oya M, Ota H, Azekura K and Yamaguchi T: Multiple primary cancer: An experience at the Cancer Institute Hospital with special reference to colorectal cancer. Int J Clin Oncol. 8:162–167. 2003. View Article : Google Scholar : PubMed/NCBI
2	Demandante CG, Troyer DA and Miles TP: Multiple primary malignant neoplasms: Case report and a comprehensive review of the literature. Am J Clin Oncol. 26:79–83. 2003. View Article : Google Scholar : PubMed/NCBI
3	Jones AS, Morar P, Phillips DE, Field JK, Husband D and Helliwell TR: Second primary tumours in patients with head and neck squamous cell carcinoma. Cancer. 75:1343–1353. 1995. View Article : Google Scholar : PubMed/NCBI
4	Aydiner A, Karadeniz A, Uygun K, Tas S, Tas F, Disci R and Topuz E: Multiple primary neoplasms at a single institution: Differences between synchronous and metachronous neoplasms. Am J Clin Oncol. 23:364–370. 2000. View Article : Google Scholar : PubMed/NCBI
5	Ries LA, Eisner MP, Kosary CL, Hankey BF, Miller BA and Clegg L: SEER Cancer Statistics Review. 1975–2000. National Cancer Institute; Bethesda, MD: 2003
6	Jiao F, Hu H and Wang LW: Quadruple primary malignancy patient with survival time more than 20 years. World J Gastroenterol. 19:1498–1501. 2003. View Article : Google Scholar
7	Jones P: Five separate malignancies in one patient. Br Med J. 1:15331976. View Article : Google Scholar : PubMed/NCBI
8	Shankar PS: Case report. Five primary cancers in one patient Postgrad Med. 61:281–282. 1977.PubMed/NCBI
9	Liu LY, Sheng SH, Zhang ZY and Xu JH: A case of matrix-producing carcinoma of the breast with micoglandular adenosis and review of literature. Int J Clin Exp Pathol. 8:8568–8572. 2015.PubMed/NCBI
10	Ye Y, Neil AL, Wills KE and Venn AJ: Temporal trends in the risk of developing multiple primary cancers: A systematic review. BMC Cancer. 16:8492016. View Article : Google Scholar : PubMed/NCBI
11	Baigrie RJ: Seven different primary cancers in a single patient. A case report and review of multiple primary malignant neoplasia. Eur J Surg Oncol. 17:81–83. 1991.PubMed/NCBI
12	Curtis RE, Freedman DM, Ron E, Ries LAG, Hacker DG, Edwards BK, Tucker MA and Fraumeni JF Jr: New malignancies among cancer survivors: SEER cancer registries, 1973–2000. National Cancer Institute; Bethesda, MD, NIH Publ.: No. 05-5302. 2006
13	Linet MS, Slovis TL, Miller DL, Kleinerman R, Lee C, Rajaraman P and Berrington de Gonzalez A: Cancer risks associated with external radiation from diagnostic imaging procedures. CA Cancer J Clin. 62:75–100. 2012. View Article : Google Scholar : PubMed/NCBI
14	Meyerhardt JA, Mangu PB, Flynn PJ, Korde L, Loprinzi CL, Minsky BD, Petrelli NJ, Ryan K, Schrag DH, Wong SL, et al: Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American society of clinical oncology clinical practice guideline endorsement. J Clin Oncol. 31:4465–4470. 2013. View Article : Google Scholar : PubMed/NCBI
15	Mathews JD, Forsythe AV, Brady Z, Butler MW, Goergen SK, Byrnes GB, Giles GG, Wallace AB, Anderson PR, Guiver TA, et al: Cancer risk in 680000 people exposed to computed tomography scans in childhood or adolescence: Data linkage study of 11 million Australians. BMJ. 346:f23602013. View Article : Google Scholar : PubMed/NCBI
16	Kim C, Bi X, Pan D, Chen Y, Carling T, Ma S, Udelsman R and Zhang Y: The risk of second cancers after diagnosis of primary thyroid cancer is elevated in thyroid microcarcinomas. Thyroid. 23:575–582. 2013. View Article : Google Scholar : PubMed/NCBI
17	Morgan DJ, Dhruva SS, Wright SM and Korenstein D: Update on medical practices that should be questioned in 2015. JAMA Intern Med. 175:1960–1964. 2015. View Article : Google Scholar : PubMed/NCBI
18	Davies L and Welch HG: Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA. 295:2164–2167. 2006. View Article : Google Scholar : PubMed/NCBI
19	Matesich SM and Shapiro CL: Second cancer after breast cancer treatment. Semin Oncol. 30:740–748. 2003. View Article : Google Scholar : PubMed/NCBI
20	Williams-Brown MY, Salih SM, Xu X, Veenstra TD, Saeed M, Theiler SK, Diaz-Arrastila CR and Salama SA: The effect of tamoxifen and raloxifene on estrogen metabolism and endometrial cancer risk. J Steroid Biochem Mol Biol. 126:78–86. 2011. View Article : Google Scholar : PubMed/NCBI
21	Breuss JM, Gillett N, Lu L, Sheppard D and Pytela R: Restricted distribution of integrin beta 6 mRNA in primate epithelial tissue. J Histochem Cytochem. 41:1521–1527. 1999. View Article : Google Scholar
22	Breuss JM, Gallo J, DeLisser HM, Klimanskaya IV, Folkesson HG, Pittet JF, Nishimura SL, Aldape K, Landers DV, Carpenter W, et al: Expression of the beta 6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling. J Cell Sci. 108:2241–2251. 1995.PubMed/NCBI
23	Bates RC, Bellovin DI, Brown C, Maynard E, Wu B, Kawakatsu H, Sheppard D, Oettgen P and Mercurio AM: Transcriptional activation of integrin beta 6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. J Clin Invest. 115:339–347. 2005. View Article : Google Scholar : PubMed/NCBI
24	Zhang ZY, Xu KS, Wang JS, Yang GY, Wang W, Wang JY, Niu WB, Liu EY, Mi YT and Niu J: Integrin alpha v beta 6 acts as a prognostic indicator in gastric carcinoma. Clin Ongol. 20:61–66. 2008. View Article : Google Scholar
25	Niu J, Gu X, Turton J, Meldrum C, Howard EW and Agrez M: Integrin-mediated signalling of gelatinase B secretion in colon cancer cells. Biochem Biophys Res Commun. 249:287–291. 1998. View Article : Google Scholar : PubMed/NCBI
26	Agrez M, Gu XH, Turton J, Meldrum C, Niu J, Antalis T and Howard EW: The alpha v beta 6 integrin induces gelatinase B secretion in colon cancer cells. Int J Cancer. 81:90–97. 1999. View Article : Google Scholar : PubMed/NCBI
27	Yang GY, Xu KS, Pan ZQ, Zhang ZY, Mi YT, Wang JS, Chen R and Niu J: Integrin alpha v beta 6 mediates the potential for colon cancer cells to colonize in and metastasize to the liver. Cancer Sci. 99:879–887. 2008. View Article : Google Scholar : PubMed/NCBI
28	Liu S, Wang J, Niu W, Liu E, Wang J, Peng C, Lin P, Wang B, Khan AQ, Gao H, et al: The β6-integrin-ERK/MAP kinase pathway contributes to chemo resistance in colon cancer. Cancer Lett. 328:325–334. 2013. View Article : Google Scholar : PubMed/NCBI
29	Yang GY, Xu KS, Pan ZQ, Zhang ZY, Mi YT, Wang JS, Chen R and Niu J: Integrin alpha v beta 6 mediates the potential for colon cancer cells to colonize in and metastasize to the liver. Cancer Sci. 99:879–887. 2008. View Article : Google Scholar : PubMed/NCBI
30	Liu S, Liang B, Gao H, Zhang F, Wang B, Dong X and Niu J: Integrin αvβ6 as a novel marker for diagnosis and metastatic potential of thyroid carcinoma. Head Neck Oncol. 5:72013.
31	Koide N, Adachi W, Koike S, Watanabe H, Yazawa K and Amano J: Synchronous gastric tumors associated with esophageal cancer: A retrospective study of twenty-four patients. Am J Gastroenterol. 93:758–762. 1998. View Article : Google Scholar : PubMed/NCBI
32	Chai W, Gong FY, Zhang WL, Wen Y and Cui LF: Multiple primary cancer in the female genital system. Medicine. 96:472017. View Article : Google Scholar